Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dazodalibep long-term extension study in Sjögren’s syndrome
2024-517513-32-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- May 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 27
01
Overview
Phase 3, open-label, single-arm trial of dazodalibep in Sjögren's syndrome, sponsored by Amgen. Primary endpoint: Incidence of treatment-emergent adverse events, treatment-emergent serious adverse events, and adverse events of special interest. Planned start May 2025; status: authorised.
02
Drugs
dazodalibep
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2024-517513-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517513-32-00.